NO20074980L - Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiker. - Google Patents

Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiker.

Info

Publication number
NO20074980L
NO20074980L NO20074980A NO20074980A NO20074980L NO 20074980 L NO20074980 L NO 20074980L NO 20074980 A NO20074980 A NO 20074980A NO 20074980 A NO20074980 A NO 20074980A NO 20074980 L NO20074980 L NO 20074980L
Authority
NO
Norway
Prior art keywords
transdermal delivery
topical
toxics
botulinum
posting
Prior art date
Application number
NO20074980A
Other languages
English (en)
Norwegian (no)
Inventor
Michael D Dake
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of NO20074980L publication Critical patent/NO20074980L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20074980A 2005-03-03 2007-10-03 Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiker. NO20074980L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65843405P 2005-03-03 2005-03-03
PCT/US2006/007830 WO2006094263A2 (fr) 2005-03-03 2006-03-03 Compositions et procedes pour l'application topique et la delivrance transdermique de toxines botuliniques

Publications (1)

Publication Number Publication Date
NO20074980L true NO20074980L (no) 2007-11-07

Family

ID=36941888

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074980A NO20074980L (no) 2005-03-03 2007-10-03 Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiker.

Country Status (16)

Country Link
US (4) US9180081B2 (fr)
EP (1) EP1861112A4 (fr)
JP (2) JP2008531732A (fr)
KR (2) KR101453963B1 (fr)
CN (3) CN106039294A (fr)
AU (1) AU2006218431B2 (fr)
BR (1) BRPI0608249A2 (fr)
CA (1) CA2599017C (fr)
CR (1) CR9351A (fr)
IL (2) IL185299A (fr)
MX (1) MX2007010673A (fr)
NO (1) NO20074980L (fr)
RU (2) RU2007136616A (fr)
SG (1) SG160357A1 (fr)
WO (1) WO2006094263A2 (fr)
ZA (1) ZA200707352B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
SG150570A1 (en) * 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2558408C (fr) 2004-03-03 2014-11-18 Essentia Biosystems, Inc. Compositions et methodes pour une application topique et une administration transdermique de toxines botuliniques
WO2006094263A2 (fr) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions et procedes pour l'application topique et la delivrance transdermique de toxines botuliniques
EP1896038B1 (fr) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Methode et composition pour l'administration transdermique de la testosterone
KR20130114229A (ko) 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물
KR20130079645A (ko) 2005-07-18 2013-07-10 유니버시티 오브 메사츄세츠 로웰 나노에멀젼 조성물 및 이의 제조 및 사용 방법
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CN101374498A (zh) 2005-12-01 2009-02-25 麻萨诸塞州洛厄尔大学 肉毒杆菌纳米乳液
WO2008070538A2 (fr) 2006-12-01 2008-06-12 Anterios, Inc. Nanoparticules à entités amphiphiles
SG10201607909WA (en) 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008082885A2 (fr) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Molécules de transport utilisant des polypeptides tat du vih à séquence inverse
AU2007340162B2 (en) * 2006-12-29 2013-08-01 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
HRP20161722T1 (hr) 2007-07-26 2017-02-10 Revance Therapeutics, Inc. Antimikrobni peptid i njegovi pripravci
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
KR102080429B1 (ko) * 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
ES2669020T3 (es) 2008-12-31 2018-05-23 Revance Therapeutics, Inc. Formulaciones inyectables de toxina botulínica
WO2010085473A1 (fr) 2009-01-20 2010-07-29 Trustees Of Tufts College Procédés pour l'administration de toxines ou de parties enzymatiquement actives correspondantes
WO2010114828A1 (fr) * 2009-04-01 2010-10-07 Revance Therapeutics, Inc. Procédé et composition de traitement des affections de la peau associées à une hyperréactivité vasculaire
JP6043627B2 (ja) * 2009-06-25 2016-12-14 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． アルブミン非含有ボツリヌス毒素製剤
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
BR112012010058A2 (pt) * 2009-10-30 2016-05-31 Duoject Inc aplicador tópico para um agente paralítico e método para aplicação do agente
US8454975B1 (en) * 2010-01-11 2013-06-04 Elizabeth VanderVeer Method for enhancing skin appearance
ES2641068T3 (es) 2011-01-07 2017-11-07 Revance Therapeutics, Inc. Composición tópica que comprende una toxina botulínica y un colorante
CN104602703A (zh) * 2012-03-22 2015-05-06 雷文斯治疗公司 使用局部化学性去神经支配剂处理皱纹的方法
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
CN103083651A (zh) * 2013-01-22 2013-05-08 南京中医药大学 用于外用制剂的穿膜肽介导的肉毒毒素的组合物及其制备方法和应用
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016092365A1 (fr) 2014-12-08 2016-06-16 JJSK R&D Pte Ltd Compositions de molécules porteuses et procédés associes
WO2016110662A1 (fr) * 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Neurotoxines cationiques
JP6813492B2 (ja) * 2015-02-03 2021-01-13 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素充填済み容器
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
EP3541358A1 (fr) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Administration transdermique de grands agents
WO2018134265A1 (fr) 2017-01-17 2018-07-26 Forrest Michael David Inhibiteurs thérapeutiques du mode inverse de l'atp synthase
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
IL271845B2 (en) 2017-07-13 2024-06-01 Michael David Forrest Therapeutic modulators of the reverse mode of atp synthase
WO2019046311A1 (fr) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. Compositions transmucosales de toxine botulique, kits et procédés de traitement de troubles de la vessie
KR20190038292A (ko) 2017-09-29 2019-04-08 한국프라임제약주식회사 효능 지속시간이 연장된 보툴리눔 독소 조성물
US10232009B1 (en) * 2017-09-29 2019-03-19 Pro Sunfun Biotech Research And Development Co., Ltd. Peptide for promoting wound healing, its composition and method of using the same
AU2018359962A1 (en) * 2017-11-03 2020-05-28 Revance Therapeutics, Inc. Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect
KR20200105829A (ko) * 2017-12-04 2020-09-09 레반스 테라퓨틱스, 아이엔씨. 주사 가능한 보툴리눔 독소 제제 및 높은 반응 속도 및 긴 효과 지속을 갖는 이의 사용 방법
BR112020012641A2 (pt) 2017-12-20 2020-12-01 Allergan, Inc. polipeptídeos de domínio de ligação celular de toxina de botulinum e métodos de uso para rejuvenescimento da pele
EP3813872A4 (fr) * 2018-06-13 2022-03-23 Dermata Therapeutics, LLC Compositions pour le traitement d'affections cutanées
CN116917134A (zh) * 2020-12-02 2023-10-20 约翰霍普金斯大学 用于神经调节剂的包封和持续释放的聚合物纳米颗粒组合物
CA3201108A1 (fr) * 2020-12-02 2022-06-09 Sashank Reddy Compositions de nanoparticules polymeres pour encapsulation et liberation prolongee de neuromodulateurs
WO2022125678A1 (fr) * 2020-12-09 2022-06-16 Dermata Therapeutics, Inc. Compositions destinées au traitement d'affections cutanées
WO2022157548A1 (fr) 2021-01-24 2022-07-28 Forrest Michael David Inhibiteurs d'utilisations cosmétiques et thérapeutiques d'atp synthase

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078060A (en) * 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4434228A (en) * 1982-04-20 1984-02-28 Genex Corporation Immobilization of biological materials in condensed polyalkyleneimine polymers
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
JPS63287730A (ja) 1987-05-20 1988-11-24 Nippon Shokubai Kagaku Kogyo Co Ltd 経皮吸収促進剤およびこれを含有してなる皮膚外用剤
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
JPH06501938A (ja) 1990-10-24 1994-03-03 アレリックス　バイオファーマシューティカルズ　アイエヌシー． ペプチドよりなるｈｉｖ複製阻害剤
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
EP0903408A3 (fr) 1992-08-21 2005-11-02 Biogen, Inc. Polypeptide de transport dérivé de la protéine tat
US5260082A (en) 1992-09-16 1993-11-09 Kraft General Foods, Inc. Baked goods, doughs or batters, dry mixes and methods for producing thereof
US5877278A (en) * 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6986893B2 (en) * 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP1488803B1 (fr) 1993-12-28 2008-03-26 Allergan, Inc. Composante neurotoxique de la toxine botulinique pour la traitement de la dystonie cervicale
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP1086702B1 (fr) * 1994-05-09 2005-04-13 BINDER, William J. Neurotoxines presynaptiques pour le traitement des cephalées de la migraine
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9600272D0 (en) 1996-01-06 1996-03-06 Univ Nottingham Polymers
WO1997040854A2 (fr) 1996-05-01 1997-11-06 Antivirals Inc. Conjugues polypeptidiques destines au transport de substances a travers des membranes cellulaires
US6444209B1 (en) * 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
FR2755976B1 (fr) 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
US6228161B1 (en) 1996-12-30 2001-05-08 Minerals Technologies Inc. Use of calcium carbonate in an acidic aqueous media
FR2759298B1 (fr) 1997-02-10 1999-04-09 Rhone Poulenc Rorer Sa Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees
CA2291074C (fr) * 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition et procede permettant d'ameliorer les transports a travers des membranes biologiques
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
WO1999024596A1 (fr) 1997-11-12 1999-05-20 Valentis, Inc. Plasmides d'expression utilises dans des vaccins a base d'acide nucleique a plusieurs epitopes
US5985434A (en) * 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
WO1999029721A1 (fr) 1997-12-10 1999-06-17 Washington University Systeme anti-pathogene et procedes d'utilisation
WO1999042091A2 (fr) * 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Compositions d'apport dans des cellules
US6011646A (en) 1998-02-20 2000-01-04 The Regents Of The Unviersity Of California Method to adjust multilayer film stress induced deformation of optics
WO1999043350A1 (fr) 1998-02-25 1999-09-02 Iomai Corporation Utilisation d'amplificateurs de penetration de la peau et d'agents de rupture de barriere afin d'augmenter la reponse immune transcutanee provoquee par une exotoxine de ribosylation d'adp
WO1999055332A1 (fr) 1998-04-27 1999-11-04 Fujisawa Pharmaceutical Co., Ltd. Compositions medicinales
US6261679B1 (en) 1998-05-22 2001-07-17 Kimberly-Clark Worldwide, Inc. Fibrous absorbent material and methods of making the same
TR200100254T2 (tr) * 1998-07-13 2001-06-21 Expression Genetics, Inc. Eriyebilir ve bakterilerle ayrışabilir bir gen iletim taşıyıcısı olarak poly-l-lysine benzeri bir poliyester.
US6280937B1 (en) * 1998-08-14 2001-08-28 Rigel Pharmaceuticals, Inc. Shuttle vectors
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
WO2000024419A1 (fr) 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methodes visant a faciliter la cicatrisation d'une plaie
JP2002532388A (ja) 1998-12-02 2002-10-02 イ・デ・エム・イミュノ−デジネ・モレキュル 生物学的分子を細胞中へ移入させやすくする新規なオリゴマーコンジュゲート
EP1137664A2 (fr) 1998-12-10 2001-10-04 Washington University Systeme de transduction de proteines et methodes d'utilisation
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
CN1320880C (zh) 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
ES2160485B1 (es) 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
US7442764B2 (en) * 1999-06-07 2008-10-28 Mirns Bio Corporation Reversible modification of amine-containing compounds
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030236214A1 (en) 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
MXPA02001857A (es) * 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6458763B1 (en) * 1999-09-17 2002-10-01 Depuy Orthopeadics Bone sialoprotein-based compositions for enhancing connective tissue repair
US6773928B1 (en) * 1999-09-22 2004-08-10 The United States Of America As Represented By The Secretary Of The Army Compositions and methods for enhancing bioassay performance
US6610820B1 (en) 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US20040109871A1 (en) * 2000-01-06 2004-06-10 Pascual David W. M cell directed vaccines
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
JP2003522154A (ja) * 2000-02-08 2003-07-22 アラーガン、インコーポレイテッド ボツリヌス毒素医薬組成物
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT411041B (de) * 2000-05-18 2003-09-25 Josef Lindenberg Verfahren zur herstellung von glasfliesen, glasbordüren, glasdekorpaneelen oder dgl.
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US20030215412A1 (en) 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
JP2002072267A (ja) * 2000-08-25 2002-03-12 National Institute For Materials Science 光機能素子、該素子用単結晶基板、およびその使用方法
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
MXPA03007358A (es) 2001-02-16 2004-12-13 Cellgate Inc Transportadores que contienen porciones de arginina separadas.
AU2002250293B2 (en) * 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
CA2367636C (fr) * 2001-04-12 2010-05-04 Lisa Mckerracher Proteines de fusion
WO2003011333A1 (fr) 2001-07-27 2003-02-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Toxine botulinique intervenant dans le traitement ou la prevention de l'acne
DE10146647A1 (de) * 2001-09-21 2003-04-24 Marc Heckmann Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis
WO2003041128A2 (fr) * 2001-11-07 2003-05-15 Pharmacia Corporation Procedes servant a favoriser l'absorption et l'accumulation nucleaire de polyamides dans des cellules eucaryotes
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
CA2469336C (fr) * 2001-12-11 2013-06-11 The Board Of Trustees Of The Leland Stanford Junior University Reactifs pour le transport de guanidinium et conjugues associes
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
AU2002360712A1 (en) * 2001-12-21 2003-07-30 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
US20030147958A1 (en) * 2002-01-29 2003-08-07 Cheol-Hee Ahn Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
AU2003216389A1 (en) 2002-02-21 2003-09-09 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
EP1572941A4 (fr) * 2002-02-26 2009-03-18 Maxygen Inc Nouveaux antigenes de flavivirus
CA2476589C (fr) * 2002-02-27 2014-02-25 Pharmain, Ltd. Compositions pour l'administration de substances therapeutiques et analogues, et procedes de fabrication et d'utilisation desdites compositions
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
CN1383811A (zh) * 2002-05-16 2002-12-11 卢伟成 一种除皱化妆品及其制作工艺
US7459164B2 (en) 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
NZ537120A (en) 2002-05-31 2008-07-31 Univ Jefferson Compositions and methods for transepithelial molecular transport
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US9265725B2 (en) * 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US6866856B2 (en) 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
US7482016B2 (en) 2003-03-19 2009-01-27 The J. David Gladstone Institutes Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
US20040192754A1 (en) 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
US20040247623A1 (en) * 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
WO2005030119A2 (fr) 2003-04-11 2005-04-07 Allergan, Inc. Peptides de toxine botulique a et procedes pour prevoir et reduire la resistance immunitaire a la therapie contre la toxine botulique
US20050074425A1 (en) * 2003-07-02 2005-04-07 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
US7883720B2 (en) * 2003-07-09 2011-02-08 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150570A1 (en) * 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
CA2558408C (fr) * 2004-03-03 2014-11-18 Essentia Biosystems, Inc. Compositions et methodes pour une application topique et une administration transdermique de toxines botuliniques
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
KR100852824B1 (ko) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
US20060024331A1 (en) 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
JP2006067889A (ja) * 2004-09-01 2006-03-16 Japan Science & Technology Agency Ｐｅｏと二本鎖核酸のコンジュゲート
WO2006094263A2 (fr) * 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions et procedes pour l'application topique et la delivrance transdermique de toxines botuliniques
SG160358A1 (en) * 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
JP2008532522A (ja) * 2005-03-08 2008-08-21 モレキュラー プローブス， インコーポレイテッド ナノ構造を用いた細胞膜電位差のモニターおよび操作
DE602006017207D1 (de) * 2005-05-11 2010-11-11 Eth Zuerich Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
DE102005039189B4 (de) 2005-08-18 2010-09-09 Siemens Ag Bildauswertungsverfahren für zweidimensionale Projektionsbilder und hiermit korrespondierende Gegenstände
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
NZ568216A (en) * 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US20100021502A1 (en) 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
AU2007340162B2 (en) * 2006-12-29 2013-08-01 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
WO2008082885A2 (fr) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Molécules de transport utilisant des polypeptides tat du vih à séquence inverse
AU2009215341B2 (en) * 2008-02-20 2015-03-26 Glaxosmithkline Biologicals S.A. Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
US20170361130A9 (en) * 2008-05-23 2017-12-21 Pankaj Modi Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
KR20110059861A (ko) * 2008-09-29 2011-06-07 파나소닉 주식회사 정보 기록 매체, 기록 방법 및 재생 방법
RU2011125776A (ru) * 2008-12-31 2013-02-10 Реванс Терапьютикс, Инк. Композиции и способы лечения гиперпигментации
ES2669020T3 (es) * 2008-12-31 2018-05-23 Revance Therapeutics, Inc. Formulaciones inyectables de toxina botulínica
WO2010114828A1 (fr) * 2009-04-01 2010-10-07 Revance Therapeutics, Inc. Procédé et composition de traitement des affections de la peau associées à une hyperréactivité vasculaire
JP6043627B2 (ja) * 2009-06-25 2016-12-14 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． アルブミン非含有ボツリヌス毒素製剤
US9737500B2 (en) * 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9504664B2 (en) * 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
ES2641068T3 (es) * 2011-01-07 2017-11-07 Revance Therapeutics, Inc. Composición tópica que comprende una toxina botulínica y un colorante
US8697090B2 (en) * 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
US8586020B2 (en) * 2011-06-30 2013-11-19 Korea Institute Of Science And Technology Poly(organophosphazene) composition for biomaterials
CA2848740A1 (fr) * 2011-09-16 2013-03-21 Mingxing Wang Polymeres cationiques amphiphiles pour l'administration d'agents therapeutiques
JP2015501844A (ja) * 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
AU2013211903A1 (en) * 2012-01-27 2014-08-21 Revance Therapeutics, Inc. Methods and assessment scales for measuring wrinkle severity
CN104602703A (zh) * 2012-03-22 2015-05-06 雷文斯治疗公司 使用局部化学性去神经支配剂处理皱纹的方法
US9541558B2 (en) * 2012-09-05 2017-01-10 California Institute Of Technology Cysteine hydrazide nicotinamide for glycomics and glycoproteomics uses
MX370929B (es) * 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10485855B2 (en) * 2014-05-01 2019-11-26 Anterios, Inc. Demonstrable efficacy across or within patient populations
RU2694820C9 (ru) * 2014-12-23 2019-08-12 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
JP6813492B2 (ja) * 2015-02-03 2021-01-13 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素充填済み容器
RU2018119765A (ru) * 2015-10-29 2019-12-02 Реванс Терапьютикс, Инк. Инъекционные препараты на основе ботулотоксина и способы их применения, обеспечивающие длительное терапевтическое и косметического действие
KR20190022476A (ko) * 2016-04-12 2019-03-06 일루스트리스 파마슈티컬즈 인코포레이티드 화합물의 국소 도포용 조성물
WO2019075263A2 (fr) * 2017-10-11 2019-04-18 Illustris Pharmaceuticals, Inc. Procédés et compositions à administration topique
CN116764087A (zh) * 2018-08-15 2023-09-19 阿勒根公司 具有活性成分的微针阵列

Also Published As

Publication number Publication date
WO2006094263A2 (fr) 2006-09-08
AU2006218431B2 (en) 2012-12-06
CN102499981A (zh) 2012-06-20
KR101453963B1 (ko) 2014-10-22
CN101171018A (zh) 2008-04-30
US9180081B2 (en) 2015-11-10
BRPI0608249A2 (pt) 2009-12-08
MX2007010673A (es) 2008-04-07
IL226612B (en) 2020-05-31
JP5883371B2 (ja) 2016-03-15
IL226612A0 (en) 2013-06-27
CN101171018B (zh) 2013-03-27
CR9351A (es) 2008-01-21
EP1861112A2 (fr) 2007-12-05
IL185299A (en) 2013-06-27
US10080786B2 (en) 2018-09-25
CN102499981B (zh) 2016-08-03
RU2007136616A (ru) 2009-04-10
AU2006218431A1 (en) 2006-09-08
IL185299A0 (en) 2008-12-29
JP2008531732A (ja) 2008-08-14
CA2599017C (fr) 2014-08-12
US20160051646A1 (en) 2016-02-25
US9314416B2 (en) 2016-04-19
EP1861112A4 (fr) 2009-07-22
US20190247293A1 (en) 2019-08-15
CA2599017A1 (fr) 2006-09-08
CN106039294A (zh) 2016-10-26
KR20140032510A (ko) 2014-03-14
US20090087457A1 (en) 2009-04-02
SG160357A1 (en) 2010-04-29
US20070077259A1 (en) 2007-04-05
KR20070110402A (ko) 2007-11-16
RU2013114743A (ru) 2014-10-10
US10744078B2 (en) 2020-08-18
ZA200707352B (en) 2009-04-29
WO2006094263A3 (fr) 2006-11-30
JP2013040185A (ja) 2013-02-28
HK1119934A1 (en) 2009-03-20

Similar Documents

Publication Publication Date Title
MX2007010673A (es) Composiciones y metodos para la aplicacion topica y el suministro transdermico de toxinas botulinicas.
Majid Clinical use of botulinum toxins in oral and maxillofacial surgery
DE60329098D1 (de) Verwendung von mastix und dessen ätherischen ölen zur verhinderung oder bekämpfung von mikrobieller infektionen
MEP25008A (en) Topical methadone compositions and methods for using the same
JP6386911B2 (ja) 外用組成物
BR112015007985A8 (pt) uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições
EA200901299A1 (ru) Композиции олигогулуроната и олигогалактуроната
NO20064490L (no) Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiner
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR122020010667B8 (pt) inibidores de quinase, seus usos, e composição farmacêutica
WO2009043987A9 (fr) Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales
WO2020046102A3 (fr) Compositions pharmaceutiques semi-solides à base huileuse contenant de la pyrphénidone à utiliser dans la réparation tissulaire
WO2021214370A3 (fr) Timbres auto-adhérents en fibres polymères pour la libération contrôlée de parfum
PH12021551759A1 (en) Cosmetic composition of liquid crystal lipid particles for personal care applications
WO2022184854A3 (fr) Formulations de protéines de fusion ace2 fc
PL1962815T3 (pl) Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne
MX2023001789A (es) Composiciones naturales para el cuidado de la piel.
MX2021008812A (es) Composicion cosmetica/dermatologica.
WO2021007091A3 (fr) Compositions cosmétiques prébiotiques et leurs procédés de préparation
CN104287982B (zh) 一种调节头皮油脂平衡的去屑组合物
MX2023010545A (es) Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
MX2009012712A (es) Nuevas 4-fenil-imidazol-2-tionas como inhibidores de la tirosinasa, su procedimiento de preparacion y su uso en medicina humana asi como en cosmetica.
Bakhtiyari et al. Pharmacological effects of medicinal plants on skin.
MX2009012714A (es) Nuevas 4-heteroail-imidazol-2-tionas como inhibidores de la tirosinasa, su procedimiento de preparacion y su uso en medicina humana asi como en cosmetica.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application